All In Biotech

Drug Trial Radar · NCT07648264

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

A Phase 3, Prospective, Open-label, Multicenter, Single-arm Study to Investigate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Subjects With Secondary Immune Deficiency Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

63

Planned (sponsor's estimate)

Start

Sep 15, 2026

Primary completion

Sep 27, 2029

Study completion Sep 27, 2029

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Jun 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20 in adults with hematologic malignancies treated with B-cell targeting Chimeric antigen receptor T-cell (CAR T-cell) and T-cell redirecting therapies (such as T-cell engager bispecific antibody \[TCE BsAb\] therapy). The primary objective is to demonstrate that true annualized rate of serious bacterial infection (SBIs) is less than (\<) 1.0. This study includes two cohorts: 1. Loading Cohort: Participants with serum immunoglobulin G (IgG) \< 500 milligrams per deciliter (mg/dL) at Screening, with or without ongoing immunoglobulin replacement therapy (IgRT) during Screening, who must have received five doses of IgPro20 during the Initial Treatment Period. 2. Maintenance-only Cohort: Participants with serum IgG greater than or equal to (≥) 500 mg/dL and ongoing IgRT at Screening, who must have received one dose of IgPro20 during the Initial Treatment Period.

Conditions

  • Secondary Immune Deficiency

Interventions

  • IgPro20Biological

    IgPro20 infusion administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Serious Bacterial Infections (SBIs) per ParticipantTime frame: Up to Month 12

Locations

60 sites in 11 countries. Site status is shown where the registry gives one.

  • UC Irvine

    Orange, California · Not yet recruiting

  • CBCI, Colorado Blood Cancer Institute

    Denver, Colorado · Not yet recruiting

  • SSAK Partners

    Coral Springs, Florida · Recruiting

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida · Not yet recruiting

  • Indiana University Health Arnett, Inc.

    Lafayette, Indiana · Not yet recruiting

  • Johns Hopkins Asthma & Allergy Center

    Baltimore, Maryland · Not yet recruiting

  • American Oncology Partners, PA dba The Center for Cancer and Blood Disorders

    Bethesda, Maryland · Recruiting

  • Hackensack Meridian Health

    Hackensack, New Jersey · Not yet recruiting

  • Carol G Simon Cancer Center

    Morristown, New Jersey · Not yet recruiting

  • David H. Koch Center for Cancer Care

    New York, New York · Not yet recruiting

  • Montefiore Medical Center PRIME

    The Bronx, New York · Not yet recruiting

  • Duke University

    Durham, North Carolina · Not yet recruiting

  • University of Cincinnati Medical Center

    Cincinnati, Ohio · Not yet recruiting

  • Penn State Hershey Medical Center

    Hershey, Pennsylvania · Not yet recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Not yet recruiting

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington · Not yet recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Not yet recruiting

  • UZ Gent

    Ghent, Belgium · Not yet recruiting

  • CHU de Liège

    Liège, Belgium · Not yet recruiting

  • Universitair ziekenhuis Antwerpen UZA

    Edegem, Antwerp, Belgium · Not yet recruiting

  • AZ Delta

    Roeselare, West-Vlaanderen, Belgium · Not yet recruiting

  • Horizon Health Network

    Fredericton, New Brunswick, Canada · Not yet recruiting

  • McGill University Health Research Institute

    Montreal, Quebec, Canada · Not yet recruiting

  • Fakultni nemocnice Kralovske Vinohrady

    Prague, Czechia · Not yet recruiting

  • UHKT Praha

    Prague, Czechia · Not yet recruiting

  • FH Ostrova

    Ostrova, CZE, Czechia · Not yet recruiting

  • FH Hradec Kralove

    Hradec Králové, Hradec Králové Region, Czechia · Not yet recruiting

  • Rigshospitalet

    Copenhagen, Denmark · Terminated

  • Zealand University Hospital

    Roskilde, Denmark · Not yet recruiting

  • Department of Medicine, Vejle Hospital

    Vejle, South Region Denmark, Denmark · Not yet recruiting

  • Centre Henri Becquerel

    Rouen, France · Not yet recruiting

  • CHU Rennes - Hopital Pontchaillou

    Rennes, ILE ET Vilaine, France · Not yet recruiting

  • CHU de Nantes-Hotel Dieu

    Nantes, Loire Atlantique, France · Not yet recruiting

  • CHU Angers - Hôpital Hôtel Dieu

    Angers, Maine Et Loire, France · Not yet recruiting

  • Centre Hospitalier Départemental Les Oudairies

    La Roche-sur-Yon, Vendée, France · Not yet recruiting

  • Universitaetsklinikum Giessen und Marburg GmbH Standort Giessen

    Giessen, Hesse, Germany · Not yet recruiting

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

    Mainz, Rhineland-Palatinate, Germany · Not yet recruiting

  • Azienda Ospedaliero Universitaria Policlinico "Gaspare Rodolico - San Marco" (Presidio G. Rodolico)

    Catania, Italy · Not yet recruiting

  • Azienda Ospedaliera Universitaria Careggi

    Florence, Italy · Not yet recruiting

  • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico

    Milan, Italy · Not yet recruiting

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.